The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Neurobiology of Alzheimer′s disease
Open accessAbstract
Alzheimer's disease (AD) is a devastating neurodegenerative disease, the most common among the dementing illnesses. The neuropathological hallmarks of AD include extracellular beta-amyloid (amyloid precursor protein (APP) deposits, intracellular neurofibrillary tangles (NFT)), dystrophic neuritis and amyloid angiopathy. The mismetabolism of APP and the defective clearance of beta amyloid generate a cascade of events including hyperphosphorylated tau (tau) mediated breakdown of microtubular assembly and resultant synaptic failure which results in AD. The exact aetiopathogenesis of AD is still obscure. The preeminent hypotheses of AD include amyloid cascade hypothesis and tau hyperphosphorylation. The amyloid hypothesis states that extracellular amyloid plaques formed by aggregates of Abeta peptide generated by the proteolytic cleavages of APP are central to AD pathology. Intracellular assembly states of the oligomeric and protofibrillar species may facilitate tau hyperphosphorylation, disruption of proteasome and mitochondria function, dysregulation of calcium homeostasis, synaptic failure, and cognitive dysfunction. The tau hypothesis states that excessive or abnormal phosphorylation of tau results in the transformation of normal adult tau into PHF-tau (paired helical filament) and NFTs. Vascular hypothesis is also proposed for AD and it concludes that advancing age and the presence of vascular risk factors create a Critically Attained Threshold of Cerebral Hypoperfusion (CATCH) which leads to cellular and subcellular pathology involving protein synthesis, development of plaques, inflammatory response, and synaptic damage leading to the manifestations of AD. Multiple other aetiological and pathogenetic hypotheses have been put forward including genetics, oxidative stress, dysfunctional calcium homeostasis, hormonal, inflammatory-immunologic, and cell cycle dysregulation with the resultant neurotransmitter dysfunctions and cognitive decline. The available therapeutic agents target only the neurotransmitter dysfunction in AD and agents specifically targeting the pathogenetic mechanisms like amyloid deposition and tau hyperphosphorylation might provide a definite therapeutic edge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Oxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
Oxidant stress and endothelial cell dysfunction
Lum, H., & Roebuck, K. A. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.4.c719 · Cited by 832
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Alzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Alzheimer's disease – do tauists and baptists finally shake hands?
Mudher, A., & Lovestone, S. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02031-2 · Cited by 514
Zhang, Y., McLaughlin, R., Goodyer, C., & LeBlanc, A. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110119 · Cited by 418
Hemming, M. L., & Selkoe, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508460200 · Cited by 332
Carro, E., & Torres-Aleman, I. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.050 · Cited by 262
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention
Iqbal, K., & Grundke‐Iqbal, I. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00225.x · Cited by 238
REVIEW: Pin1 in Alzheimer's disease
Butterfield, D. A., Abdul, H. M., Opii, W., Newman, S. F., Joshi, G., Ansari, M. A., & Sultana, R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03995.x · Cited by 179
Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease
PAKASKI, M., & KALMAN, J. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.06.005 · Cited by 178
Glutamate–glutamine cycling in Alzheimer's disease
WALTON, H., & DODD, P. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.10.007 · Cited by 174
Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease
Moore, A. H., & O’Banion, M. K. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00162-x · Cited by 171
Aliev, G., Smith, M. A., Seyidova, D., Neal, M. L., Lamb, B. T., Nunomura, A., Gasimov, E. K., Vinters, H. V., Perry, G., LaManna, J. C., et al. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00419.x · Cited by 168
Non-Cholinergic Strategies for Treating and Preventing Alzheimer??s Disease
Doraiswamy, P. M. (2002) · CNS Drugs · doi:10.2165/00023210-200216120-00003 · Cited by 148
Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid
Yan, Z., & Feng, J. (2004) · Current Alzheimer Research · doi:10.2174/1567205043331992 · Cited by 96
The cell cycle as a therapeutic target for Alzheimer's disease
Neve, R. L., & McPhie, D. L. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.09.005 · Cited by 92
Functional Neurochemistry of Alzheimers Disease
Gsell, W., Jungkunz, G., & Riederer, P. F. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043386473 · Cited by 71
Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism
Wellington, C. L. (2004) · Clinical Genetics · doi:10.1111/j.0009-9163.2004.00280.x · Cited by 67
Serotoninergic impairment and aggressive behavior in Alzheimers diseaseplanar lipid bilayer
Ζάρρος, Α., Kalopita, K., & Tsakiris, S. (2005) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2005-1563 · Cited by 25
Role of Amyloid Precursor Protein, Amyloid-β and γ-Secretase in Cholesterol Maintenance
Hartmann, T. (2006) · Neurodegenerative Diseases · doi:10.1159/000095271 · Cited by 23
Cited by
Du, H., Guo, L., Fang, F., Chen, D., A Sosunov, A., M McKhann, G., Yan, Y., Wang, C., Zhang, H., Molkentin, J. D., et al. (2008) · Nature Medicine · doi:10.1038/nm.1868 · Cited by 932
Mehta, D., Jackson, R., Paul, G., Shi, J., & Sabbagh, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323868 · Cited by 607
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Fakhoury, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170720095240 · Cited by 479
Metadata
- Authors
- Mohandas, E., Rajmohan, V, & Raghunath, B.
- Venue
- Indian Journal of Psychiatry
- Publisher
- Medknow
- Published
- 2009
- Volume
- 51
- Issue
- 1
- Pages
- 55
- ISSN
- 0019-5545 (ISSN-L)
- OpenAlex
- W2034228495
- Cited by
- 268
- References
- 25
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.